Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
8 results:

  • 1. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
    Principe DR
    Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Trk receptor tyrosine kinases in metastasis and cancer therapy.
    Regua AT; Doheny D; Arrigo A; Lo HW
    Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A novel microRNA located in the
    Dokanehiifard S; Yasari A; Najafi H; Jafarzadeh M; Nikkhah M; Mowla SJ; Soltani BM
    J Biol Chem; 2017 May; 292(18):7566-7577. PubMed ID: 28100780
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
    Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.